Oppenheimer analyst Christopher Glynn downgraded Emerson (EMR) to Perform from Outperform without a price target The firm shuffled ratings in the industrials group. It cites valuation for the downgrade of Emerson. The company’s growth prospects are now reflected in the stock’s valuation, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: